Clinical course of stage IV invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hye Ryun Kim, Hye Jeong Lee, ByoungChul Cho, Hyo Sup Shim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction An invasive mucinous adenocarcinoma (IMA) is a distinct lung adenocarcinoma variant. The characteristics of stage IV IMAs are relatively unclear since most previous studies described resected cases from stage I to III. The present study aimed to investigate the clinical course of stage IV IMAs and compare the findings to those of stage IV invasive non-mucinous adenocarcinomas (INMAs). Methods The study included 36 IMA patients and 210 INMA patients. The clinicopathological parameters, treatment methods and responses, overall survival (OS), and progression-free survival (PFS) were evaluated. Results IMAs were predominantly located in the lower lobes and frequently presented with multifocal consolidation and lung-to-lung or pleural metastasis. KRAS mutations were noted in 60.0% of the examined IMAs. Non-TKI chemotherapy (CTx) was used in 72.2% of the IMA patients. OS was significantly better in untreated IMA patients than in untreated INMA patients. IMA patients treated with non-TKI CTx had no improvement of OS compared to the untreated IMA patients. However, among INMA patients, OS was best with TKIs in patients harbouring targetable mutations, followed by non-TKI CTx. IMA and INMA patients treated with non-TKI CTx had similar PFS. Conclusions Stage IV IMAs have distinct clinicopathological characteristics, and they might be less aggressive than INMAs. Since non-TKI CTx might not be beneficial in IMA patients, new therapeutic approach is necessary.

Original languageEnglish
Pages (from-to)82-88
Number of pages7
JournalLung Cancer
Volume102
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Mucinous Adenocarcinoma
Adenocarcinoma
Survival
Disease-Free Survival
Adenocarcinoma of lung
Lung
Mutation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Cha, Yoon Jin ; Kim, Hye Ryun ; Lee, Hye Jeong ; Cho, ByoungChul ; Shim, Hyo Sup. / Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. In: Lung Cancer. 2016 ; Vol. 102. pp. 82-88.
@article{281f517858bd413a90e80f8d82b51f0b,
title = "Clinical course of stage IV invasive mucinous adenocarcinoma of the lung",
abstract = "Introduction An invasive mucinous adenocarcinoma (IMA) is a distinct lung adenocarcinoma variant. The characteristics of stage IV IMAs are relatively unclear since most previous studies described resected cases from stage I to III. The present study aimed to investigate the clinical course of stage IV IMAs and compare the findings to those of stage IV invasive non-mucinous adenocarcinomas (INMAs). Methods The study included 36 IMA patients and 210 INMA patients. The clinicopathological parameters, treatment methods and responses, overall survival (OS), and progression-free survival (PFS) were evaluated. Results IMAs were predominantly located in the lower lobes and frequently presented with multifocal consolidation and lung-to-lung or pleural metastasis. KRAS mutations were noted in 60.0{\%} of the examined IMAs. Non-TKI chemotherapy (CTx) was used in 72.2{\%} of the IMA patients. OS was significantly better in untreated IMA patients than in untreated INMA patients. IMA patients treated with non-TKI CTx had no improvement of OS compared to the untreated IMA patients. However, among INMA patients, OS was best with TKIs in patients harbouring targetable mutations, followed by non-TKI CTx. IMA and INMA patients treated with non-TKI CTx had similar PFS. Conclusions Stage IV IMAs have distinct clinicopathological characteristics, and they might be less aggressive than INMAs. Since non-TKI CTx might not be beneficial in IMA patients, new therapeutic approach is necessary.",
author = "Cha, {Yoon Jin} and Kim, {Hye Ryun} and Lee, {Hye Jeong} and ByoungChul Cho and Shim, {Hyo Sup}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.lungcan.2016.11.004",
language = "English",
volume = "102",
pages = "82--88",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. / Cha, Yoon Jin; Kim, Hye Ryun; Lee, Hye Jeong; Cho, ByoungChul; Shim, Hyo Sup.

In: Lung Cancer, Vol. 102, 01.12.2016, p. 82-88.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical course of stage IV invasive mucinous adenocarcinoma of the lung

AU - Cha, Yoon Jin

AU - Kim, Hye Ryun

AU - Lee, Hye Jeong

AU - Cho, ByoungChul

AU - Shim, Hyo Sup

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Introduction An invasive mucinous adenocarcinoma (IMA) is a distinct lung adenocarcinoma variant. The characteristics of stage IV IMAs are relatively unclear since most previous studies described resected cases from stage I to III. The present study aimed to investigate the clinical course of stage IV IMAs and compare the findings to those of stage IV invasive non-mucinous adenocarcinomas (INMAs). Methods The study included 36 IMA patients and 210 INMA patients. The clinicopathological parameters, treatment methods and responses, overall survival (OS), and progression-free survival (PFS) were evaluated. Results IMAs were predominantly located in the lower lobes and frequently presented with multifocal consolidation and lung-to-lung or pleural metastasis. KRAS mutations were noted in 60.0% of the examined IMAs. Non-TKI chemotherapy (CTx) was used in 72.2% of the IMA patients. OS was significantly better in untreated IMA patients than in untreated INMA patients. IMA patients treated with non-TKI CTx had no improvement of OS compared to the untreated IMA patients. However, among INMA patients, OS was best with TKIs in patients harbouring targetable mutations, followed by non-TKI CTx. IMA and INMA patients treated with non-TKI CTx had similar PFS. Conclusions Stage IV IMAs have distinct clinicopathological characteristics, and they might be less aggressive than INMAs. Since non-TKI CTx might not be beneficial in IMA patients, new therapeutic approach is necessary.

AB - Introduction An invasive mucinous adenocarcinoma (IMA) is a distinct lung adenocarcinoma variant. The characteristics of stage IV IMAs are relatively unclear since most previous studies described resected cases from stage I to III. The present study aimed to investigate the clinical course of stage IV IMAs and compare the findings to those of stage IV invasive non-mucinous adenocarcinomas (INMAs). Methods The study included 36 IMA patients and 210 INMA patients. The clinicopathological parameters, treatment methods and responses, overall survival (OS), and progression-free survival (PFS) were evaluated. Results IMAs were predominantly located in the lower lobes and frequently presented with multifocal consolidation and lung-to-lung or pleural metastasis. KRAS mutations were noted in 60.0% of the examined IMAs. Non-TKI chemotherapy (CTx) was used in 72.2% of the IMA patients. OS was significantly better in untreated IMA patients than in untreated INMA patients. IMA patients treated with non-TKI CTx had no improvement of OS compared to the untreated IMA patients. However, among INMA patients, OS was best with TKIs in patients harbouring targetable mutations, followed by non-TKI CTx. IMA and INMA patients treated with non-TKI CTx had similar PFS. Conclusions Stage IV IMAs have distinct clinicopathological characteristics, and they might be less aggressive than INMAs. Since non-TKI CTx might not be beneficial in IMA patients, new therapeutic approach is necessary.

UR - http://www.scopus.com/inward/record.url?scp=85003953081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003953081&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.11.004

DO - 10.1016/j.lungcan.2016.11.004

M3 - Article

C2 - 27987593

AN - SCOPUS:85003953081

VL - 102

SP - 82

EP - 88

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -